Skip to main content

CTAD: New aducanumab subanalysis bolsters phase III trials in very mild Alzheimer’s

Primary tabs

View
Get Stamp Tags
Published Locations

Breadcrumb

Home
CTAD: New aducanumab subanalysis bolsters phase III trials in very mild Alzheimer’s

User login

Username

Password

Reset your password

Type	Lead	score